| Bioactivity | Vasonatrin Peptide (VNP) TFA is a chimera of atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP). Vasonatrin peptide TFA possesses the venodilating actions of CNP, the natriuretic actions of ANP, and unique arterial vasodilating actions not associated with either ANP or CNP. Vasonatrin Peptide TFA protects the diabetic heart against ischemia-reperfusion injury by inhibiting ER stress via the cGMP-PKG signaling pathway[1][2][3]. | ||||||
| Invitro | Vasonatrin Peptide (VNP) markedly enhances adiponectin mRNA expression, as well as protein secretion, however, suppresses IL-6 production in mature adipocytes. In addition, VNP significantly increases the intracellular levels of cGMP. The effects of VNP are mimicked by 8-br-cGMP, whereas inhibits by HS-142-1, or KT-5823[2]. | ||||||
| Name | Vasonatrin Peptide (VNP) (TFA) | ||||||
| Sequence | Gly-Leu-Ser-Lys-Gly-Cys-Phe-Gly-Leu-Lys-Leu-Asp-Arg-Ile-Gly-Ser-Met-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr (Disulfide bridge: Cys6-Cys22) | ||||||
| Shortening | GLSKGCFGLKLDRIGSMSGLGCNSFRY (Disulfide bridge: Cys6-Cys22) | ||||||
| Formula | C126H199N36O38S3F3 | ||||||
| Molar Mass | 2979.39 | ||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||
| Storage | Sealed storage, away from moisture
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
Vasonatrin Peptide (VNP) (TFA)
CAS: F: C126H199N36O38S3F3 W: 2979.39
Vasonatrin Peptide (VNP) TFA is a chimera of atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP). Vaso
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.